Nova Labs CJC-1295 with DAC (2mg Peptide)

CJC-1295 with DAC is a modified growth hormone-releasing hormone (GHRH) analogue investigated for its role in stimulating endogenous growth hormone release. The addition of Drug Affinity Complex (DAC) extends the peptide’s half-life by promoting binding to serum proteins, allowing for prolonged activity.

It is studied for its effects on growth hormone and insulin-like growth factor-1 (IGF-1) pathways in experimental settings.

Key Features:

• 2mg CJC-1295 with DAC per vial

• Long-acting GHRH analogue with extended half-life due to DAC modification

• Investigated for stimulation of endogenous growth hormone release

• Associated in research with modulation of IGF-1 pathways

• Studied in relation to recovery, metabolic regulation, and tissue maintenance

• Commonly explored in longevity and performance-focused research settings

Suggested Use:
For research purposes only. Protocols vary depending on study design and should be determined by qualified professionals in an appropriate setting.

Storage:

• Lyophilized form: Store in a cool, dry place (15–25°C), protected from light. Refrigeration (2–8°C) optional for extended storage

• After reconstitution: Store at 2–8°C. Do not freeze. Use within a limited timeframe

Important Information:
This product is an investigational compound and is not approved for human or veterinary use. Intended strictly for laboratory research purposes. Not for use by individuals under 18, pregnant or breastfeeding individuals, or for any therapeutic application. Ensure compliance with applicable regulations.